Immunocore Holdings (IMCR) EBT (2021 - 2026)

Immunocore Holdings (IMCR) has reported EBT for 6 consecutive years, with $13.3 million the latest figure, recorded in Q1 2026.

• Quarterly EBT rose 118.15% year-over-year to $13.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.9 million (up 47.69% YoY) and the FY2025 annual result came in at -$19.1 million, up 63.92% from the prior year.
• EBT improved to $13.3 million in Q1 2026 per IMCR's latest filing, from -$15.8 million in the prior quarter.
• Over the last five years, EBT for IMCR reached as high as $13.3 million in Q1 2026 and fell as low as -$27.4 million in Q4 2022.
• A 5-year average of -$10.2 million and a median of -$13.0 million in 2024 frame the typical range for EBT.
• Annual changes were most pronounced in 2024 — EBT jumped 733.52% — and 2025, when it plunged 95.01%.
• Year by year, EBT stood at -$27.4 million in 2022, then rose by 6.33% to -$25.6 million in 2023, then increased by 3.2% to -$24.8 million in 2024, then jumped by 36.37% to -$15.8 million in 2025, then soared by 184.03% to $13.3 million in 2026.
• According to Business Quant data, EBT over the past three periods registered $13.3 million, -$15.8 million, and $304000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.